CHICAGO – Reactions were somewhat muted as the lid came off Roche Holding AG's data from the Aphinity trial, the phase III experiment in 4,805 women with HER2-positive breast cancer, showing that to add a second HER2-targeted medicine, Perjeta (pertuzumab), on top of standard-of-care Herceptin (trastuzumab) after surgery may help, but the benefit was not especially powerful. Jefferies analyst Jeffrey Holford called the results "at the bottom of expectations" and said in a research report that Aphinity hit the target, "but only just."